Get started

Financials · LSTA

Lisata Therapeutics Inc. (LSTA) financials

For the twelve months ended Jun 30, 2026, Lisata Therapeutics Inc. reported $100.0K of revenue and -$14.62M of net income.

Revenue, TTM
$100.0K
Revenue growth, YoY
-90.7%
Net income, TTM
-$14.62M
Net margin
-14621.0%
Free cash flow, TTM
-$12.32M
EPS, diluted, TTM
-$1.64
Cash
$10.44M
P/S
111.28
Market cap
$11.1M
Annual revenue$170.0K
FY2016FY2025
Annual net income-$16.59M
FY2016FY2025
Annual free cash flow-$15.98M
FY2016FY2025

LSTA revenue and earnings growth

LSTA revenueQ2 2026$0

Quarter YoY
-100.0%
FY YoY
-83.0%
10Y CAGR
-38.6%

LSTA revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $170.0K, down 83.0% from fiscal 2024. Compound annual growth was -38.6% over 10 years.

LSTA net incomeQ2 2026-$2.93M

LSTA net income was -$2.93M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$4.66M a year earlier. For the full fiscal 2025 it was -$16.59M, compared with -$19.98M in fiscal 2024.

LSTA EPSQ2 2026-$0.32

LSTA diluted EPS was -$0.32 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.54 a year earlier. For the full fiscal 2025 it was -$1.91, compared with -$2.40 in fiscal 2024.

LSTA free cash flowQ2 2026-$2.65M

LSTA free cash flow was -$2.65M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$3.96M a year earlier. For the full fiscal 2025 it was -$15.98M, compared with -$19.36M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$170.0K$1.00M$0$0-----$35.28M
Cost of revenue---------$31.14M
Gross profit---------$4.15M
Research and development$7.95M$11.33M$12.73M$13.07M$17.58M$9.25M$10.80M$7.59M$15.84M$16.70M
Selling, general and admin$10.43M$12.07M$12.97M$14.14M$11.47M$9.89M$9.29M$9.39M$11.75M$12.80M
Operating income-$18.21M-$22.41M-$25.71M-$57.60M-$29.05M-$19.14M-$20.09M-$16.99M-$27.59M-$29.50M
Interest expense------$0$5.0K$378.0K$1.78M
Pre-tax income-$17.55M-$20.78M-$23.17M-$56.70M-$28.97M-$19.01M-$19.35M-$16.17M-$27.70M-$31.26M
Income tax-$962.0K-$798.0K-$2.33M-$2.48M-$1.51M-$10.87M$0$0-$11.53M$0
Net income-$16.59M-$19.98M-$20.84M-$54.23M-$27.47M-$8.15M-$19.36M-$16.17M$22.98M-$32.66M
EPS, basic-$1.91-$2.40-$2.58-$10.47-$7.45-$7.95-$28.20-$25.05$38.40-$74.85
EPS, diluted-$1.91-$2.40-$2.58-$10.47-$7.45-$7.95-$28.20-$25.05$38.40-$74.85
Diluted shares8.7M8.3M8.1M5.2M3.7M1.0M688,333.333645,933.333597,933.333436,550.067

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$15.96M$16.21M$22.59M$32.15M$24.65M$16.51M$14.03M$10.30M$34.17M$7.08M
Receivables$0$900.0K$0-----$234.5K$138.8K
Current assets$17.70M$34.58M$53.92M$71.88M$96.18M$35.33M$25.97M$44.11M$61.40M$24.65M
Goodwill---------$7.01M
Total assets$17.74M$35.00M$54.69M$73.03M$97.01M$36.00M$27.15M$44.58M$63.38M$53.51M
Current liabilities$3.07M$5.61M$6.59M$6.38M$4.52M$3.51M$5.98M$5.62M$9.31M$21.18M
Short-term debt--------$0$3.13M
Long-term debt--------$0$2.52M
Total debt--------$0$5.65M
Total liabilities$3.14M$5.68M$6.80M$6.71M$5.01M$3.76M$6.60M$7.13M$13.19M$30.05M
Shareholders' equity$14.86M$29.32M$47.89M$66.32M$92.00M$32.24M$20.55M$37.45M$50.19M$4.07M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$15.95M-$19.36M-$20.03M-$21.17M-$22.25M-$8.82M-$18.88M-$19.99M-$20.88M-$23.67M
Capital expenditures$28.0K$0$0$285.0K$60.0K$20.0K$0$134.0K$135.0K$1.10M
Free cash flow-$15.98M-$19.36M-$20.03M-$21.45M-$22.30M-$8.84M-$18.88M-$20.12M-$21.01M-$24.77M
Investing cash flow$15.09M$13.23M$10.10M$28.91M-$54.90M-$7.28M$21.43M-$4.71M$41.27M-$2.85M
Financing cash flow$599.0K-$206.0K$385.0K-$224.0K$85.28M$18.58M$1.18M$824.0K-$932.0K$20.90M
Stock-based compensation$1.23M$1.65M$2.04M-------
Depreciation and amortization$146.0K$174.0K$189.0K$69.0K$55.0K$63.0K$100.0K$200.0K$400.0K$500.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-83.0%--------56.9%
Gross margin---------11.8%
Operating margin-10711.2%-2240.9%--------83.6%
Net margin-9756.5%-1998.5%--------92.6%
Free cash flow margin-9398.2%-1935.6%--------70.2%
Return on equity-111.7%-68.2%-43.5%-81.8%-29.9%-25.3%-94.2%-43.2%45.8%-803.2%
Return on assets-93.5%-57.1%-38.1%-74.2%-28.3%-22.6%-71.3%-36.3%36.3%-61.0%
Current ratio5.766.168.1811.2621.2710.084.357.856.591.16
Debt to equity--------0.001.39

Source: XBRL data Lisata Therapeutics Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Nov 7, 2013; 1-for-10, first reported Aug 9, 2016; 1-for-15, first reported Nov 10, 2022.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

LSTA peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
LSTA$100.0K-90.7%-$14.62M-14621.0%$11.1M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

LSTA FAQ

8 questions
  • What is LSTA revenue?
    Lisata Therapeutics Inc. (LSTA) reported $100.0K of revenue for the twelve months ended Jun 30, 2026. That is down 90.7% from the year before. Revenue for fiscal 2025 was $170.0K.
  • Is LSTA profitable?
    No. Lisata Therapeutics Inc. reported a net loss of $14.62M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does LSTA have?
    Lisata Therapeutics Inc. reported $10.44M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is LSTA revenue growing?
    Lisata Therapeutics Inc.'s revenue changed -83.0% in fiscal 2025, to $170.0K. Its compound annual growth rate was -38.6% over 10 years.
  • What is LSTA free cash flow?
    Lisata Therapeutics Inc. generated -$12.32M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$12.32M less capital expenditures.
  • What is LSTA earnings per share?
    Diluted earnings per share were -$1.64 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did LSTA last report financial results?
    The latest statements here come from Lisata Therapeutics Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.
  • Where does this LSTA financial data come from?
    Quantisnow builds these statements from the structured XBRL data Lisata Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.